Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

177.40 -0.66 (-0.37%)
Official Closing Price Updated: 4:10 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
3 Dividend Growers That Fly Under the Radar
These three companies may have what it takes to continue to build on their strong history of dividend payments even if the economy continues to sour. 
Via MarketBeat
Topics Earnings Economy
A Gathering Storm: U.S. Economy Grapples with Recessionary Headwinds
The United States economy is facing an increasingly complex and concerning confluence of risk factors, raising the specter of a looming recession. A deteriorating labor market, persistently high... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
Navigating the Shifting Sands: A Comprehensive Economic Outlook for 2025
As the global economy marches into 2025, it finds itself at a critical juncture, balancing the promise of moderate growth against the persistent shadows of tenacious inflation, geopolitical... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
Recession Radar: A Divergent Outlook on America's Economic Future
The U.S. economy finds itself at a crossroads, with leading financial institutions and economic forecasters presenting a varied, yet generally cautious, outlook on the probability of a recession. From... 
Via MarketMinute
Topics Bonds Economy Supply Chain
Stalling Job Market Rings Alarm Bells: August Employment Data Signals Economic Headwinds and Intensified Rate Cut Expectations
The latest U.S. employment report for August 2025 has sent a palpable chill through financial markets and economic forecasts, confirming a significant deceleration in the nation's labor market.... 
Via MarketMinute
Topics Bonds Economy Workforce
Federal Reserve's Unexpected September Hold: A Looming Market Shock and an Estimated 8% S&P 500 Plunge
Financial markets are currently on edge, grappling with the looming possibility of a significant shock: an unexpected decision by the Federal Reserve to forgo a widely anticipated interest rate cut in... 
Via MarketMinute
Topics Bonds ETFs Economy
September's Shadow: Will the Notorious 'September Effect' Offer Bargains or Bring Bigger Bears to Wall Street?
As autumn leaves begin to fall, a familiar chill often descends upon the financial markets, not just in temperature but in investor sentiment. September has historically earned a notorious reputation... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
S&P 500's 22x Forward P/E: A Precarious Peak or Justified Premium?
The S&P 500's current forward price-to-earnings (P/E) ratio, hovering around 22x, has ignited a fervent debate across financial markets. This elevated valuation metric, significantly above historical... 
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
If You'd Invested $1,000 in Johnson & Johnson (JNJ) Stock 5 Years Ago, Here's How Much You'd Have Today
The answer might surprise you. 
Via The Motley Fool
Navigating the Storm: Diversification and Hedging Amidst Unprecedented Market Volatility
The global financial landscape is currently grappling with a potent concoction of heightened market instability, pervasive policy uncertainty, and an escalating array of geopolitical events. These... 
Via MarketMinute
Topics Artificial Intelligence Bonds Climate Change
The Lingering Shadow: Sticky Inflation and Central Banks' Tightrope Walk in 2025
Global financial markets in 2025 are navigating a complex landscape shaped by persistently high, or "sticky," inflation and the increasingly cautious stance of major central banks regarding interest... 
Via MarketMinute
Topics Bonds Economy Supply Chain
The Dawn of a New Era: How GLP-1s, AI, and Robotic Surgery Are Reshaping Healthcare and Investment
The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
Income Under Pressure: Why Covered Calls Are Capturing Investor Attention in Turbulent Markets
In an era defined by persistent market volatility and an ongoing search for reliable income streams, a historically potent, yet sometimes overlooked, options strategy is experiencing a significant... 
Via MarketMinute
Topics Bonds Derivatives ETFs
The Enduring Allure of Dividends: Blue-Chip Stocks as a Bedrock for Income and Growth
In an ever-fluctuating financial landscape, where market volatility and economic uncertainties often dominate headlines, the timeless appeal of dividend-paying stocks continues to shine as a classic... 
Via MarketMinute
Topics ETFs Economy
Small-Cap and Value Stocks Poised for Resurgence as Federal Reserve Rate Cuts Loom
The financial markets are on the cusp of a significant "Great Rebalancing," with small-cap and value stocks emerging from a prolonged period of underperformance to challenge the dominance of mega-cap... 
Via MarketMinute
Topics Economy Supply Chain
Jim Cramer Says Johnson & Johnson Stock Could Power Through $200 Next
Johnson & Johnson investors focus on its pharma strength, legal strategy shift, and growth in medical devices amid sector challenges. 
Via Benzinga
Global Storm Brews: International Headwinds Force Fed's Hand in Pivotal Policy Decisions
The global economy is currently navigating a treacherous landscape, marked by a confluence of significant headwinds that are increasingly dictating the Federal Reserve's monetary policy path.... 
Via MarketMinute
Topics Economy Supply Chain World Trade
7 No-Brainer Robotics Stocks to Buy Right Now
These robotics leaders are positioned to capitalize as AI transforms machines from tools into intelligent partners. 
Via The Motley Fool
Topics Artificial Intelligence
Johnson & Johnson's FDA-Approved Bladder Cancer Drug Offers New Option For Patients Avoiding Surgery
The FDA approved Johnson & Johnson's Inlexzo, offering a new bladder cancer treatment option with high response rates for patients, avoiding surgery. 
Via Benzinga
The Specter of Stagflation: A Looming Threat to Global Markets
The global economy is once again grappling with the disquieting prospect of stagflation, a rare and challenging economic phenomenon defined by the simultaneous occurrence of slow economic growth, high... 
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
Global Growth Hits the Brakes: A Mixed Economic Picture Emerges for 2025 and Beyond
The global economy is bracing for a significant slowdown, with leading financial institutions projecting a challenging landscape for 2025 and the years to follow. A confluence of escalating trade... 
Via MarketMinute
Topics Economy Supply Chain World Trade
The Federal Reserve Under Siege: A Threat to Monetary Policy Independence
Concerns are escalating over the Federal Reserve's long-standing independence as political pressure intensifies, raising fundamental questions about the future of U.S. monetary policy and its... 
Via MarketMinute
Topics Bonds Economy Government
Johnson & Johnson Kicks Off 'Powerful New Product Cycle': Analyst
Johnson & Johnson analyst Asad Haider says Inlexzo is currently the only intravesical iDRS to deliver cancer meds directly into the bladder. 
Via Benzinga
Navigating the Tempest: An Investor's Guide to the Volatile Bond Market of 2025
The global bond market is braced for continued turbulence in 2025, presenting a complex landscape for investors seeking stability and returns. A confluence of persistent inflation, central bank policy... 
Via MarketMinute
Topics Bonds Economy Retirement
Yield Curve Steeps Amidst Weakening Labor Market: A Looming Recession or Strategic Pivot for the US Economy?
The United States Treasury yield curve, a bellwether for economic sentiment, has undergone a dramatic transformation around April 2025, shifting from a historically prolonged inversion to a distinct... 
Via MarketMinute
Topics Bonds Economy Workforce
How Do Investors Really Feel About Johnson & Johnson?
 
Via Benzinga
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential... 
Via Benzinga
Topics ETFs Government
Investors Brace for Critical CPI Report as Inflation Nears 3% Hurdle
Financial markets are holding their breath as the highly anticipated August 2025 Consumer Price Index (CPI) report looms, a critical barometer for inflation and a potential swing factor for the Federal... 
Via MarketMinute
Topics Bonds Economy World Trade
Will Sticky Services and Tariffs Spoil the Fed's Rate Cut Plans?
Despite widespread market expectations for a September interest rate cut, the Federal Reserve finds itself navigating a perilous economic landscape marked by persistently high inflation. Stubbornly... 
Via MarketMinute
Topics Economy World Trade
Johnson & Johnson: A 6.9 Rating and What It Means for Investors
What does the future hold for Johnson & Johnson? In this episode, we break down the company's strengths, challenges, and what investors can expect moving forward. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.